Amgen Inc. (AMGN) stock analysis

Healthcare · Drug Manufacturers - General

From the 10-K filed 2026-02-13

How it makes money

It sells specialized medicines to patients, but profit levels depend heavily on coverage decisions made by government and commercial third-party payers.

It derives revenue from human therapeutics, with profitability determined by its ability to navigate the complex reimbursement landscape. Because it must secure access through these payers, its realized net selling price often faces downward pressure, requiring high volume growth to offset pricing declines.

Ultimately, its earnings are tied to the willingness of health systems to include its drugs in their formularies and pay for them at negotiated rates.

What protects it: the moat

It asserts that it maintains a competitive advantage through its pipeline and manufacturing capabilities, though it faces increasing competition from biosimilars and generics.

Management claims its competitive position is bolstered by a robust pipeline of first-in-class medicines and a world-class manufacturing network. It actively seeks to expand these capabilities through new R&D facilities and global manufacturing capacity.

However, it acknowledges that its intellectual property is subject to legal challenges and that market exclusivity is pressured by the rise of biosimilar and generic alternatives.

What growth costs

It requires significant ongoing investment in R&D to maintain its pipeline and in physical manufacturing infrastructure to support global product supply.

To grow, it must fund intensive clinical trials and invest in physical facilities across multiple locations. It directs substantial capital toward both maintaining existing operations and constructing new, state-of-the-art research and development centers.

What could damage it

A production failure at its primary manufacturing hub in Puerto Rico could cause a severe and immediate disruption to its global medicine supply.

Because the company concentrates the vast majority of its commercial manufacturing activities in a single facility in Puerto Rico, a disaster or operational collapse at that location would leave it unable to fulfill orders, effectively halting the engine that produces its human therapeutics revenue.

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

More on AMGN

Other companies in Drug Manufacturers - General